Related Experiment Videos
T-cell-rich lymphoproliferative disorders. Morphologic and immunologic differential diagnoses
C D Winberg1, K Sheibani, J S Burke
1Division of Pathology, City of Hope National Medical Center, Duarte, California 91010.
Cancer
|October 15, 1988
Summary
T11 (CD2) positivity is a useful marker for identifying T-cell lymphomas and reactive lymphoproliferative disorders. However, some peripheral T-cell lymphomas with a polymorphous appearance may show reduced T11 expression, necessitating further diagnostic evaluation.
Area of Science:
- Hematology
- Immunology
- Oncology
Background:
- Peripheral T-cell lymphomas (PTCL) are a heterogeneous group of lymphoid malignancies.
- Accurate differentiation of PTCL from other lymphoproliferative disorders (LPD) is crucial for effective treatment.
- T-cell specific markers are essential tools in diagnosing lymphoid neoplasms.
Purpose of the Study:
- To evaluate the utility of T11 (CD2) monoclonal antibody studies in differentiating PTCL.
- To identify lymphoproliferative disorders with a high T-cell content.
- To determine the reliability of T11 positivity as a T-cell marker in various LPD.
Main Methods:
- Analysis of T11 (CD2) monoclonal antibody reactivity on cell suspensions from 509 lymph nodes.
- Categorization of LPD based on the percentage of T11-positive cells.
- Comparison of T11 expression patterns across different types of lymphomas and reactive conditions.
Main Results:
- 52% of cell suspensions showed more than 50% T11-positive cells.
- High T11 positivity (>50%) was observed in over 75% of diffuse mixed cell lymphomas, mycosis fungoides, and true histiocytic lymphoma.
- T11 expression was generally reliable, except in PTCL with a polymorphous appearance, which tended to lose T11 expression.
Conclusions:
- T11 positivity serves as a reliable T-cell marker in most reactive and neoplastic LPD.
- A multi-parameter diagnostic approach is necessary for T11-negative PTCL, small lymphocytic PTCL, SIg-negative B-cell lymphomas, minimal disease lymphomas, and polymorphous large cell proliferations.